Eli Lilly is continuing its investment in manufacturing by allocating an additional $3 billion to enhance production capabilities. The pharmaceutical company aims to ramp up the manufacturing of its blockbuster drugs and future products.
One of the key initiatives includes expanding a factory in Kenosha County, Wisconsin, which was acquired earlier this year. This expansion will cater to the increasing demand for injectable products such as Mounjaro and Zepbound, which collectively generated $4.4 billion in sales for Lilly in the third quarter of this year.
The construction for the expansion project is scheduled to commence next year. In addition to the Wisconsin facility, Lilly has also announced significant manufacturing expansion projects near its headquarters in Indianapolis earlier in the year.
Since 2020, Eli Lilly and Co. has committed over $23 billion towards constructing, expanding, or acquiring manufacturing sites globally. This strategic investment underscores the company's commitment to meeting the growing market demand for its pharmaceutical products.
